VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BCPCBalchem Corporation
$171.22$5.5B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksBCPCCash Flow

Balchem Corporation (BCPC) Cash Flow Statement

30Y historyFree accessUpdated daily

Operational efficiency remains high, evidenced by a 1.72x OCF/NI conversion ratio in 2025Q4, which supports the company's ability to fund shareholder returns.

BCPC Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations220.16M216.56M182M183.76M138.54M160.51M150.49M124.46M118.7M110.62M107.61M103.83M85.35M55.69M53.78M44.9M39.03M48.07M22.9M15.64M16.37M13.7M12.14M11.15M10.11M3.22M5.95M4.7M3.9M3M3.6M
Operating CF Margin %-20.88%19.08%19.92%14.7%20.09%21.39%19.34%18.44%18.6%19.45%18.79%15.77%16.52%17.33%15.38%15.3%21.91%9.87%8.87%16.22%1.63%18.02%18.03%16.8%6.98%17.93%15.82%13.59%10.49%13.64%
Operating CF Growth %71.32%18.99%-0.96%32.64%-13.69%6.66%20.92%4.86%7.3%2.79%3.65%21.65%53.25%3.55%19.77%15.04%-18.81%109.95%46.43%-4.48%19.51%12.79%8.89%10.27%213.9%-45.88%26.66%20.51%30%-16.67%125%
Net Income158.08M154.84M128.47M108.54M105.37M96.1M84.62M79.67M78.57M90.07M55.97M59.72M52.83M44.87M40.01M38.77M33.28M26.79M19.05M16.12M12.28M10.95M8.03M5.64M7.42M5.11M3.73M3.1M3M2.8M1.9M
Depreciation & Amortization47.17M45.69M47.97M54.94M51.85M48.88M51.28M45.86M44.67M44.38M46.2M39.96M30.52M10.47M9.64M9.29M8.56M8.13M7.79M6.38M3.44M2.81M3.27M3.52M2.92M2.62M2.02M2M1.7M1.1M1.4M
Stock-Based Compensation19.6M18.06M16.68M16.05M13.22M10.8M8.3M7.6M6.41M6.26M7.02M6.83M4.56M3.82M4.22M3.69M3.99M3.08M01.64M00000000000
Deferred Taxes115K6.26M-6.78M-10.81M-8.36M-5.94M-4.63M-3.56M-5.4M-28.78M-6.88M-2.86M-11.26M-315K-92K307K-669K-1.22M-238K-617K104K599K1.39M598K1.02M112K-168K-100K100K0-100K
Other Non-Cash Items-20.12M-835K1.77M-4.96M1.68M-257K2.38M-146K-1.54M663K562K273K493K92K145K682K-439K763K2.82M199K1.44M470K586K309K458K501K299K200K100K200K100K
Working Capital Changes15.31M-7.46M-6.12M20.01M-25.22M10.93M8.53M-4.96M-4.01M-1.98M4.73M-105K8.21M-3.25M-134K-7.83M-5.69M10.53M-6.55M-8.07M-897K-1.13M-1.13M1.08M-1.69M-5.12M78K-500K-1M-1.1M300K
Change in Receivables10.07M-20.85M5.58M6.97M-3.62M-20.7M-3.6M11.62M-7.77M-3.91M-15.66M10.81M-8.39M2.96M-7.64M-2.7M-2.74M862K0-15.41M00000000000
Change in Inventory12.9M3.63M-22.79M10.53M-7.8M-21.02M13.92M-11.4M-6.02M-319K4.75M3.13M6.7M-3.94M-1.98M-3.01M-1.86M2.66M-974K481K-827K-1.5M-358K1.28M-1.66M-3.02M194K100K-400K-600K0
Change in Payables737K11.29M9.06M3.55M-15.54M46.19M-3.85M1.13M5.99M1.51M17.84M-15.72M7.75M-2.77M5.78M-2.52M-1.4M6.82M07.63M00000000000
Cash from Investing-44.27M-43.89M-59.74M-34.81M-416.01M-35.3M-34.59M-156.22M-31.99M-42.7M-133.59M-42.28M-504.42M-8.38M-14M-6.61M-11.05M-3.64M-5.56M-45.77M-25.23M-12.94M-1.23M-2.31M-9.95M-16.35M-956K-700K-5.7M-1.8M-2.3M
Capital Expenditures5.56M-43.49M-35.66M-37.89M-50.29M-37.45M-33.83M-28.41M-19.72M-28.09M-23.99M-42.31M-13.37M-8.42M-14M-6.64M-7.56M-3.64M-5.26M-5.04M-2.36M-1.77M-1.22M-2.27M-10.02M-1.95M-881K-600K-1.6M-1.1M-1M
CapEx % of Revenue0.53%4.19%3.74%4.11%5.34%4.69%4.81%4.41%3.06%4.72%4.34%7.66%2.47%2.5%4.51%2.27%2.96%1.66%2.27%2.86%2.34%0.21%1.8%3.67%16.65%4.23%2.65%2.02%5.57%3.85%3.79%
Acquisitions0-49K-24.16M-1.54M-365.78M318K87K-141.06M-17.4M-17.39M-110.6M34K-491.06M000-4.66M0-296K-40.74M-22.87M-11.42M000000000
Investments-------------------------------
Other Investing-49.86M089K1.88M56K1.83M-850K13.25M5.13M2.79M1M34K-168K40K-121K28K1.17M0011K0245K-14K-44K69K-14.4M-75K-100K-4.1M500K-1.3M
Cash from Financing-155.62M-152.81M-133.81M-153.32M246.68M-102.18M-101.16M43.38M-71.45M-68.63M-19.45M-25.84M261.67M16.46M-9.84M-632K3.18M-1.53M-16.12M27.09M1.05M-493K-7.42M-1.33M-1.55M13.18M-3.63M-3.6M2.4M-500K-1.4M
Debt Issued (Net)1K-26.19M-119.78M-131.22M300.83M-55.16M-85.15M75M-63.52M-64.38M-16.88M-35M256.86M0-1.21M-3.56M-1.36M-4.8M-15.87M26.79M00-9.58M-1.74M-1.74M13.06M-1.25M-2.5M2.2M-600K-1.4M
Equity Issued (Net)-102.31M-98.33M-5.68M-4.47M-35.42M-35.24M-13.46M-21.32M-1.39M-1.91M5.6M11.4M-1.07M-1.93M206K4.34M-937K01.05M1.22M1.24M211K2.56M807K515K511K-2.06M-900K300K200K0
Dividends Paid-30.79M-28.29M-25.58M-22.87M-20.71M-18.72M-16.7M-15.13M-13.43M-12.07M-10.72M-9.25M-7.86M0-11.7M-4.31M-3.09M-2.01M-1.98M-1.6M-1.04M-685K-389K-382K-305K-277K-245K-200K-200K-100K-100K
Share Repurchases-118M-107.64M-5.68M-4.47M-35.42M-35.24M-13.46M-21.32M-1.39M-1.91M-1.59M-1.21M-1.07M-1.93M-1.7M-109K-937K0000-1.2M0000-2.24M-900K000
Other Financing-22.57M017.23M5.24M1.98M6.94M14.15M4.84M6.9M9.73M2.55M7.01M13.73M18.39M2.86M2.89M8.57M5.28M672K677K861K-19K-14K-14K-20K-123K-71K0100K0100K
Net Change in Cash22.97M25.05M-14.93M-2.11M-36.68M18.67M18.9M11.4M13.85M1.77M-46.15M34.51M-158.46M64.01M29.96M37.53M30.82M43.01M1.11M-2.88M-7.81M262K3.5M7.51M-1.39M52K1.37M400K600K700K-100K
Free Cash Flow182.23M173.07M146.34M145.87M88.25M123.06M116.67M96.05M98.97M82.52M83.62M61.52M71.98M47.27M39.78M38.27M31.47M44.43M17.64M10.6M14.01M11.93M10.93M8.88M94K1.27M5.07M4.1M2.3M1.9M2.6M
FCF Margin %17.23%16.69%15.34%15.81%9.36%15.4%16.58%14.92%15.38%13.87%15.12%11.13%13.3%14.02%12.81%13.11%12.34%20.25%7.6%6.01%13.88%1.42%16.22%14.36%0.16%2.76%15.28%13.8%8.01%6.64%9.85%
FCF Growth %20.88%18.27%0.32%65.3%-28.29%5.48%21.47%-2.96%19.93%-1.31%35.93%-14.54%52.26%18.85%3.95%21.58%-29.16%151.93%66.43%-24.37%17.44%9.14%23.04%9350%-92.61%-74.92%23.71%78.26%21.05%-26.92%420%
FCF per Share5.645.314.474.502.723.773.592.953.052.562.621.942.311.531.311.271.061.540.620.380.510.440.420.350.000.050.210.160.090.080.11
FCF Conversion (FCF/Net Income)1.15x1.40x1.42x1.69x1.31x1.67x1.78x1.56x1.51x1.23x1.92x1.74x1.62x1.24x1.34x1.16x1.17x1.79x1.20x0.97x1.33x1.25x1.51x1.98x1.36x0.63x1.60x1.52x1.30x1.07x1.89x
Interest Paid7.59M10.6M17.7M25.93M11.88M4.55M4.67M06.94M7.02M6.67M5.99M4.68M40K6K84K111K00000000000000
Taxes Paid36.31M37.75M42.64M35.73M33.02M25.36M22.64M020.59M25.84M30.74M19.55M25.3M12.1M14.84M17.66M17.35M00000000000000

Key Metrics

Growth RegimeExpanding
ProfitabilityStrong
Balance SheetFortress
Cash FlowRobust
Top Statement Risk

Ethylene Oxide Regulatory Exposure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

High Quality Earnings Conversion Observed

Based on reported financial data, Balchem consistently demonstrates strong cash conversion, with the OCF/NI ratio frequently exceeding 1.0, as evidenced by the 1.72x conversion rate recorded in 2025Q4, suggesting that reported net income is well-supported by actual cash generation from core operations.

The consistent ability to generate operating cash flow in excess of net income indicates a high quality of earnings, largely devoid of aggressive accrual accounting. Investors should monitor whether this trend persists as the company navigates potential regulatory-driven capital expenditure requirements.

FCF Margins Reflect Operational Efficiency

As reported in recent quarterly filings, Balchem maintains a resilient free cash flow trajectory, with margins peaking at 24.4% in 2023Q4, which underscores the company's ability to convert its specialized chemical revenue into significant liquidity despite periodic fluctuations in working capital requirements.

The stability of these margins suggests that the company's business model is inherently cash-generative and less capital-intensive than traditional commodity chemical peers. This trajectory provides management with the flexibility to pursue tuck-in acquisitions without relying on external debt financing.

Disciplined Capital Expenditure Strategy Maintained

According to historical cash flow statements, Balchem exhibits a disciplined approach to capital intensity, with CapEx/Revenue ratios remaining largely in the low-to-mid single digits, such as the 2.2% observed in 2025Q1, reflecting a focus on maintenance rather than aggressive capacity expansion.

This low capital intensity is a hallmark of the company's niche market positioning, where intellectual property and regulatory barriers provide the primary competitive moat. Future increases in this ratio may indicate necessary investments in emission control technologies to comply with evolving environmental standards.

Working Capital Volatility Warrants Monitoring

Based on the provided cash flow data, Balchem experiences notable swings in working capital, including a significant $32.5 million inflow in 2023Q4 followed by a $15.3 million outflow in 2025Q1, which suggests that inventory and receivables management remains sensitive to seasonal or cyclical demand shifts.

These fluctuations appear to be a byproduct of the company's supply chain complexity and the timing of large-scale sterilization canister shipments. Analysts should interpret these movements as operational noise rather than a fundamental deterioration in the company's ability to collect cash from its customer base.

Conservative Capital Allocation Strategy Prevails

As indicated by recent financial statements, Balchem utilizes its robust cash flow primarily for shareholder returns and strategic tuck-in acquisitions, with share repurchases totaling $53.6 million in 2025Q4, highlighting a management philosophy that prioritizes capital return over aggressive balance sheet expansion.

The company's reliance on internal cash to fund both dividends and buybacks reinforces its fortress balance sheet status. This approach suggests that management remains cautious regarding large-scale M&A, preferring to maintain liquidity for potential regulatory contingencies or smaller, high-return intellectual property acquisitions.

BCPC — Frequently Asked Questions

Quick answers to the most common questions about buying BCPC stock.

How much cash does Balchem Corporation (BCPC) generate from operations?

Balchem Corporation (BCPC) generated $216.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Balchem Corporation's free cash flow?

Balchem Corporation (BCPC) generated $173.1M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Balchem Corporation's capital expenditure (CapEx)?

Balchem Corporation (BCPC) spent $43.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Balchem Corporation distribute cash to shareholders?

In 2025, Balchem Corporation (BCPC) returned $28.3M to shareholders via cash dividends and spent $107.6M on share repurchases. This shows the company's commitment to returning capital to its equity investors.